STAT February 29, 2024
Helen Branswell

The new vaccines that protect older adults against respiratory syncytial virus, or RSV, may be linked to a small increased risk of developing Guillain-Barré syndrome, new data from the Centers for Disease Control and Prevention and the Food and Drug Administration suggest.

At a meeting Thursday of the Advisory Committee on Immunization Practices, vaccine safety experts from the two agencies presented data that showed what appears to be an elevated rate of GBS, as the condition is called, among people who got the Pfizer vaccine, although there were also cases detected among people who got the GSK product.

But the experts cautioned that it is too early to determine if there is a true increased risk of developing GBS after...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Public Health / COVID
Drugmakers prep for bird flu outbreak, despite continued low risk
How AI, Tech, And Policy Can Stop The Wildfire Crisis
Bird flu crisis enters new phase
Federal health webpages pulled as healthcare braces for tariffs: 5 updates
Confusion over federal funding freeze prompts public health concerns

Share This Article